ClinicalTrials.gg
RecruitingNCT07062562SPRINTUpdated Nov 10, 2026

The Effect of Repeated Whole-body NMES Sessions With or Without Protein Intake on Muscle Protein Synthesis During 3 Days of Bed Rest in Healthy Young Volunteers

An interventional study of Sham (No Treatment) and NMES in Muscle Wasting, sponsored by Wageningen University. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Wageningen University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Muscular Atrophy with a site in Netherlands — 3 open to participants now, 5 under way, 2 of them phase 3. Muscular Atrophy · Netherlands.

Planned enrollment
11th of 18
42 · median 55
Started
2025
the only one that year
No phase
10 of 21
3 open now
Registered
20th of 21
by date
Lead sponsor
2 of 21
Wageningen University

Among the 21 studies in Muscular Atrophy with a site in Netherlands, this one is the 11th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2025, is one of 10 with no phase, and was the 20th registered.

Muscular Atrophy

413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.

Browse Muscular Atrophy studies →

Open to participants now

3 of the 21 studies in Muscular Atrophy with a site in Netherlands are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Muscular Atrophy with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this clinical trial is to examine the effect of whole-body electrostimulation with protein intake on muscle protein synthesis, muscle mass and function during bed rest in healthy young adults (18-35 years). The main questions to answer are:

  • Does whole-body NMES followed by protein intake improve muscle protein synthesis rates during 3 days of bed rest?
  • Does repeated NMES sessions offer protective effects on muscle mass and function during extended periods of inactivity?

Researchers will compare sham electrical electrostimulation, electrical stimulation and electrical stimulation + protein groups to see if whole-body electrostimulation combined with protein intake offers the greatest improvement in muscle protein metabolism and muscle preservation.

Participants will:

  • Undergo 3 days of bed rest while receiving one of the following interventions:

    • Sham-NMES followed by standard nutrition (CON)
    • Whole-body NMES followed by standard nutrition(NMES)
    • Whole-body NMES followed by a bolus of 20g protein (NMES+PRO)
  • Receive heavy water (D2O) to assess body water turnover.
  • Undergo leg extension exercises to assess muscle function.
  • Have quadriceps muscle thickness measured via ultrasound.
  • Provide saliva samples for analysis.
  • Have calf circumference measured to monitor changes in muscle mass.
Read the detailed description

Patients admitted to the hospital often experience prolonged bed rest, which can lead to rapid muscle loss and weakness. In the intensive care unit (ICU), this condition, known as ICU-acquired weakness (ICU-AW), affects up to 50% of patients and can lead to longer mechanical ventilation times, increased morbidity, and a reduced quality of life after hospital discharge. One of the key reasons for muscle loss during bed rest is an impaired response to dietary protein, which normally helps maintain muscle mass.

Neuromuscular electrical stimulation (NMES) is a method that uses small electrical currents to stimulate muscle contractions, potentially counteracting muscle loss during periods of inactivity. Previous research has shown that NMES applied to the quadriceps muscles can reduce muscle loss in sedated patients and improve muscle protein synthesis in individuals with type 2 diabetes. However, the effects of whole-body NMES in combination with timed protein intake on muscle protein metabolism during bed rest are still unknown.

This study aims to investigate the impact of both a single session and repeated sessions of whole-body NMES, with or without subsequent protein intake, on muscle protein synthesis rates, muscle mass, and function during 3 days of bed rest in healthy young adults.

Study Design:

This is a randomized, placebo-controlled clinical trial with three parallel groups. Participants will be randomly assigned to one of the following groups:

  • Control Group (CON): Sham-NMES + standard nutrition
  • NMES Group (NMES): Whole-body NMES + standard nutrition
  • NMES + Protein Group (NMES+PRO): Whole-body NMES + 20g protein bolus

Study Procedures:

Participants will be healthy adults (18-35 years, male and female) and will undergo the following procedures:

  • 3 days of strict bed rest to simulate hospitalization-related muscle disuse
  • Neuromuscular electrical stimulation (NMES) sessions to assess its effect on muscle metabolism
  • Muscle biopsies to measure changes in muscle protein synthesis at the molecular level
  • Consumption of deuterium oxide (D₂O or "heavy water") to track muscle protein turnover
  • Multiple blood and saliva samples to analyze protein metabolism markers
  • Leg extension tests to assess changes in muscle function
  • Quadriceps muscle thickness measurements via ultrasound
  • Calf circumference measurements to assess muscle mass changes

This study will provide critical insights into how NMES and protein intake can help counteract muscle loss and weakness during hospitalization and may contribute to the development of more effective rehabilitation strategies for ICU and bedridden patients.

03

Conditions studied

  • Muscle Wasting

Browse trials for

Keywords

  • NMES
  • Skeletal Muscle Metabolism
  • Protein
  • Disuse
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged from 18-35 years
  • 18.5 \< \< 30 kg·m2
  • Recreationally active (performing non-competitive physical exercise at least one time per week for minimally 30 minutes)

Exclusion criteria

Exclusion Criteria:

  • Employed or undertaking a thesis or internship at the department of Human and Animal Physiology at Wageningen University
  • Smoking
  • Diabetes (Type 1, Type 2, or genetic form of diabetes)
  • Any diagnosed cardiovascular (heart) disease or high blood pressure (≥140 mmHg systolic and/or

    ≥90 mmHg diastolic)

  • Chronic use of any prescribed or over the counter pharmaceuticals (excluding oral and contraceptive devices)
  • Known allergy to lidocaine
  • Prone to keloid forming (i.e. hyperplastic growth of scars)
  • All co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g.

arthritis, spasticity/rigidity, all neurological disorders and paralysis)

  • Regular use of dietary protein and/or amino acid supplements (>3 times per week)
  • Currently involved in a structured progressive resistance training programme (>3 times per week)
  • A personal or family history of thrombosis (clots), epilepsy, seizures, or schizophrenia
  • Any previous motor disorders or disorders in muscle and/or lipid metabolism
  • Any back, leg, knee, neck, shoulder or postural complaints
  • Presence of an ulcer in the stomach or gut and/or strong history of indigestion
  • for DXA scans (e.g. undergoing radiologic examination)
  • Lactose intolerance
  • Known severe kidney problems
  • Pregnant or breastfeeding
  • Unable to give consent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
42 participants (estimated)

Study arms

  • Sham comparator
    Control group

    Sham-NMES with standard nutrition

    Other: Sham (No Treatment) · Other: Standard nutrition

  • Active comparator
    Whole-body NMES group

    Whole-body NMES stimulation with standard nutrition

    Other: NMES · Other: Standard nutrition

  • Active comparator
    Whole-body NMES + protein group

    Whole-body NMES with a 20g protein bolus on top of the standard nutrition

    Other: NMES · Dietary Supplement: Protein bolus (20g) · Other: Standard nutrition

Interventions

  • OtherSham (No Treatment)

    A placebo treatment in which no actual electrical stimulation is delivered, serving as a control for the active NMES.

  • OtherNMES

    Active neuromuscular electrical stimulation applied to the entire body to induce muscle contractions through small electric currents.

  • Dietary supplementProtein bolus (20g)

    A bolus dose of 20 grams of protein provided after the NMES intervention to assess the combined effect of muscle stimulation and protein intake on muscle protein metabolism.

  • OtherStandard nutrition

    Provision of a normal Western standardized diet.

06

What researchers measure

Primary outcomes

  1. Cumulative myofibrillar fractional synthesis rate

    A measure of muscle protein synthesis between two given time points.

    Time frame: Habitual MPS (Day -2 to Day 0), Acute effect of NMES (+protein bolus) (0 hours to 5 hours on Day 0), Bedrest MPS (Day 0 to Day 3),

Secondary outcomes

  1. Quadriceps Muscle Layer Thickness

    Assessed using ultrasound, this measures changes in muscle size, indicating muscle loss or preservation during bed rest and NMES intervention.

    Time frame: Between Day -21 and Day -5, Day 0, Day 3, Day 6, Week 6

  2. Body Composition

    Evaluates muscle mass to determine overall changes.

    Time frame: Day 0 and Day 3.

  3. Body composition

    Evaluates fat distribution to determine overall changes.

    Time frame: Time Frame: Day 0 and Day 3.

  4. Quadriceps Muscle Function

    Assessed via a leg dynamometer.

    Time frame: Between Day -21 and Day -5, Day 0, Day 3, Day 6, Week 6

  5. Quadriceps Muscle Strength

    Assessed via a leg dynamometer.

    Time frame: Between Day -21 and Day -5, Day 0, Day 3, Day 6, Week 6

  6. Handgrip Strength

    Assessed via a hand dynamometer.

    Time frame: Between Day -21 and Day -5, Day 0, Day 3, Day 6, Week 6

  7. Whole-Body Nitrogen Balance

    The balance between nitrogen intake (from dietary protein) and nitrogen loss (through urine and other excretions)

    Time frame: Day 0 to Day 3

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

Of 170 non-industry interventional studies with no phase under Muscular Atrophy, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 24 months is close to that.

Counting every sponsor, half of 176 studies reached it within 21 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
Jul 14, 2025
StartActual
May 22, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07062562
Responsible party
Marlou Dirks (Assistant Professor, Wageningen University) — Principal investigator
First posted
Jul 14, 2025
Start date
May 22, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Marlou Dirks, PhD
Contact
marlou.dirks@wur.nl
+31 317 480 100

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion